☆ 4.4 Letter

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

HAEMATOLOGICA (2016)

Get Full Text
Add to Collection

Journal

HAEMATOLOGICA
Volume 101, Issue 7, Pages 295-298

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2015.140806

Keywords

CC-292; single-agent; chronic lymphocytic leukemia; small lymphocytic lymphoma; relapsed; refractory; BTK inhibitors

Categories

Hematology

Funding

  1. NCI NIH HHS [P30 CA060553] Funding Source: Medline

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.